Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI
Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1242-1251
DOI: 10.1177/22143602261433495 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 13.03.2026. Verfasst von Charlotte Colot und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Neurology and Neuromuscular Reference Center, Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)- Hôpital Universitair…. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Tongue, Lip, Muscle Strength. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds De La Recherche Scientifique - FNRS.
Abstract (Originalsprache)
Background
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease characterized by muscular atrophy and respiratory and bulbar dysfunction, especially in the most severe phenotypes (SMA type 0 and 1). Swallowing function remains understudied because assessment tools are often unavailable or poorly tolerated by young children. The Iowa Oral Performance Instrument (IOPI), that measures orofacial strength via a small air-filled bulb has recently been evaluated in SMA type 2 and 3 patients.
Objective
The purpose of this study was to investigate muscle strength of several muscles used during the oral phase of swallowing using IOPI in SMA type 1 children treated with nusinersen compared to healthy controls. In addition, it sought to correlate labial and lingual pressures with known key predictors of phenotype severity (Children's Hospital Of Philadelphia Infant Test of Neuromuscular Disorders [CHOP INTEND], age at first symptoms, SMN2 copy number) and indicators of feeding-nutritional status (p-FOIS (Pediatric Functional Oral Intake Scale)).
Methods
Combining results from four independent centers, we recruited 22 individuals with a confirmed genetic diagnosis of symptomatic SMA type 1. All patients had been treated with nusinersen for at least 2.5 years and had undergone at least one IOPI measurement at a median age of 5.4 years. IOPI data were compared to age- and gender-matched controls and published normative data when available.
Results
Oral pressures were lower in patients than in typically developing children (lips: p < 0.01; tongue: p < 0.001). Weaker labial pressure was significantly correlated with younger age at disease onset (r = 0.66; p = 0.0053), older age at first nusinersen injection (r = -0.52; p = 0.0326), lower body mass index (r = 0.61; p = 0.0149), and worse motor performance as expressed by the CHOP INTEND score (r = 0.60; p = 0.0170). Weaker tongue pressure was significantly correlated with younger age at disease onset (r = 0.49; p = 0.0372) and lower p-FOIS (r = 0.526; p = 0.022).
Conclusions
IOPI measurements objectively demonstrate orofacial weakness in this population compared with healthy controls and may serve as a biomarker to monitor the impact of comprehensive management, including disease-modifying therapies, on oral swallowing function in SMA type 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Neurology and Neuromuscular Reference Center, Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)- Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, B…
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova; Paediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Neurorehabilitation Unit, The NeMo Clinical Center in Milan, University of Milan, Milan, Italy.
- Centro Clinico Nemo, Fondazione Serena Onlus, Milan, Italy.
- Department of Paediatric Neurology, Neuromuscular Reference Center (NMRC) Ghent University Hospital (UZ Gent), Ghent, Belgium.
- Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
ORCID-Profile: Pablo Ruiz Chicaiza
Förderung
- Fonds De La Recherche Scientifique - FNRS
Zitieren
APA
Colot, C., Trucco, F., Ruiz Chicaiza, P., Everaert, E., Muys, S., Tahon, V., Van Himme, L., Devos, E., Vanlander, A., Lizio, A., Salmin, F., Coratti, G., Albamonte, E., Stanca, G., Pane, M., Mercuri, E., Sansone, V., & Deconinck, N. (2026). Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI. Journal of Neuromuscular Diseases, 13(6), 1242-1251. https://doi.org/10.1177/22143602261433495
Vancouver
Colot C, Trucco F, Ruiz Chicaiza P, Everaert E, Muys S, Tahon V, et al. Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI. Journal of Neuromuscular Diseases. 2026;13(6):1242-1251. doi:10.1177/22143602261433495
BibTeX
@article{Colot2026,
author = {Colot, Charlotte and Trucco, Federica and Ruiz Chicaiza, Pablo and Everaert, Elke and Muys, Sarah and Tahon, Valentine and Van Himme, Linde and Devos, Elke and Vanlander, Arnaud and Lizio, Andrea and Salmin, Francesca and Coratti, Giorgia and Albamonte, Emilio and Stanca, Giulia and Pane, Marika and Mercuri, Eugenio and Sansone, Valeria and Deconinck, Nicolas},
title = {Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
volume = {13},
number = {6},
pages = {1242--1251},
doi = {10.1177/22143602261433495}
}
EUVIMED